ArticleLeukemia2013

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.

K M Bernot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.